Skip to main content

Table 4 Patients with EF or GLS changes and their peak hs-TnT

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Prevention strategySexAgeEjection FractionGlobal StrainPeak hs-TnT
PreC3EndPreC3End
DexrazoxaneM6560.55555.2NANANA39.37
DexrazoxaneF3857.154.750.2−20.8−20.4−16.311.01
DexrazoxaneF4370.265.361.1−25.9−21.9−21.910.29
DexrazoxaneF4957.751.551.6−21.1−17.5−164.6
ContinuousM7161.355.455.6−22.9−19.1−15.844.07
ContinuousF2460.753.955.3−20.4−19.6−18.110.77
ContinuousM4057.249.952−19.3−18.1− 19.36.13
Cross OverF4262.360.255.8−21−22.4−20.13.76
  1. NA not available, due to technical limitation